Microglia P2Y6 receptors mediate nitric oxide release and astrocyte apoptosis

Journal of Neuroinflammation

Glória Queiroz¹  Jorge Gonçalves¹  Lucília Saraiva²  Clara Pereira³  Diana Pinho¹  Clara Quintas¹ 

[1] Department of Drug Sciences, Laboratory of Pharmacology, REQUIMTE and Center for Drug Discovery and Innovative Medicines, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira n° 228, Porto 4050-313, Portugal;Department of Biological Sciences, Laboratory of Microbiology, REQUIMTE and Center for Drug Discovery and Innovative Medicines, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira n° 228, Porto 4050-313, Portugal;Present address: IBMC, Instituto de Biologia Molecular e Celular, Rua do Campo Alegre 823, Porto 4150-180, Portugal

关键词: apoptosis;    nitric oxide;    P2Y6 receptors;    uracil nucleotides;    microglia;    astroglial proliferation;    lipopolysaccharide;   

Others  :  1150920
DOI  :  10.1186/s12974-014-0141-3

 received in 2014-04-15, accepted in 2014-07-28,  发布年份 2014

【 摘 要 】

Background

During cerebral inflammation uracil nucleotides leak to the extracellular medium and activate glial pyrimidine receptors contributing to the development of a reactive phenotype. Chronically activated microglia acquire an anti-inflammatory phenotype that favors neuronal differentiation, but the impact of these microglia on astrogliosis is unknown. We investigated the contribution of pyrimidine receptors to microglia-astrocyte signaling in a chronic model of inflammation and its impact on astrogliosis.

Methods

Co-cultures of astrocytes and microglia were chronically treated with lipopolysaccharide (LPS) and incubated with uracil nucleotides for 48 h. The effect of nucleotides was evaluated in methyl-[³H]-thymidine incorporation. Western blot and immunofluorescence was performed to detect the expression of P2Y₆ receptors and the inducible form of nitric oxide synthase (iNOS). Nitric oxide (NO) release was quantified through Griess reaction. Cell death was also investigated by the LDH assay and by the TUNEL assay or Hoechst 33258 staining.

Results

UTP, UDP (0.001 to 1 mM) or PSB 0474 (0.01 to 10 ?M) inhibited cell proliferation up to 43?±?2% (n?=?10, P <0.05), an effect prevented by the selective P2Y₆ receptor antagonist MRS 2578 (1 ?M). UTP was rapidly metabolized into UDP, which had a longer half-life. The inhibitory effect of UDP (1 mM) was abolished by phospholipase C (PLC), protein kinase C (PKC) and nitric oxide synthase (NOS) inhibitors. Both UDP (1 mM) and PSB 0474 (10 ?M) increased NO release up to 199?±?20% (n?=?4, P <0.05), an effect dependent on P2Y₆ receptors-PLC-PKC pathway activation, indicating that this pathway mediates NO release. Western blot and immunocytochemistry analysis indicated that P2Y₆ receptors were expressed in the cultures being mainly localized in microglia. Moreover, the expression of iNOS was mainly observed in microglia and was upregulated by UDP (1 mM) or PSB 0474 (10 ?M). UDP-mediated NO release induced apoptosis in astrocytes, but not in microglia.

Conclusions

In LPS treated co-cultures of astrocytes and microglia, UTP is rapidly converted into UDP, which activates P2Y₆ receptors inducing the release of NO by microglia that causes astrocyte apoptosis, thus controlling their rate of proliferation and preventing an excessive astrogliosis.

【 授权许可】

   
2014 Quintas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 1.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Sofroniew MV, Vinters HV: Astrocytes: biology and pathology. Acta Neuropathol 2010, 119:7-35.
• [2]Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
• [3]Pekny M, Nilsson M: Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
• [4]Cavanagh JB: The proliferation of astrocytes around a needle wound in the rat brain. J Anat 1970, 106:471-487.
• [5]Buffo A, Rolando C, Ceruti S: Astrocytes in the damaged brain: molecular and cellular insights into their reactive response and healing potential. Biochem Pharmacol 2010, 79:77-89.
• [6]Zhang D, Hu X, Qian L, O'Callaghan JP, Hong JS: Astrogliosis in CNS pathologies: is there a role for microglia? Mol Neurobiol 2010, 41:232-241.
• [7]Hanisch UK: Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
• [8]Saijo K, Glass CK: Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011, 11:775-787.
• [9]Cacci E, Ajmone-Cat MA, Anelli T, Biagioni S, Minghetti L: In vitro neuronal and glial differentiation from embryonic or adult neural precursor cells are differently affected by chronic or acute activation of microglia. Glia 2008, 56:412-425.
• [10]Ajmone-Cat MA, Mancini M, De Simone R, Cilli P, Minghetti L: Microglial polarization and plasticity: evidence from organotypic hippocampal slice cultures. Glia 2013, 61:1698-1711.
• [11]Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J: Regeneration of adult axons in white matter tracts of the central nervous system. Nature 1997, 390:680-683.
• [12]Franke H, Verkhratsky A, Burnstock G, Illes P: Pathophysiology of astroglial purinergic signalling. Purinergic Signal 2012, 8:629-657.
• [13]Sperlagh B, Illes P: Purinergic modulation of microglial cell activation. Purinergic Signal 2007, 3:117-127.
• [14]Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA: International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006, 58:281-341.
• [15]Lecca D, Ceruti S: Uracil nucleotides: from metabolic intermediates to neuroprotection and neuroinflammation. Biochem Pharmacol 2008, 75:1869-1881.
• [16]Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K: UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 2007, 446:1091-1095.
• [17]Wang M, Kong Q, Gonzalez FA, Sun G, Erb L, Seye C, Weisman GA: P2Y nucleotide receptor interaction with alpha integrin mediates astrocyte migration. J Neurochem 2005, 95:630-640.
• [18]Queiroz G, Gebicke-Haerter PJ, Schobert A, Starke K, von Kugelgen I: Release of ATP from cultured rat astrocytes elicited by glutamate receptor activation. Neuroscience 1997, 78:1203-1208.
• [19]Queiroz G, Meyer DK, Meyer A, Starke K, von Kugelgen I: A study of the mechanism of the release of ATP from rat cortical astroglial cells evoked by activation of glutamate receptors. Neuroscience 1999, 91:1171-1181.
• [20]Quintas C, Fraga S, Goncalves J, Queiroz G: Opposite modulation of astroglial proliferation by adenosine 5'-O-(2-thio)-diphosphate and 2-methylthioadenosine-5'-diphosphate: mechanisms involved. Neuroscience 2011, 182:32-42.
• [21]Cunha RA, Sebastiao AM, Ribeiro JA: Inhibition by ATP of hippocampal synaptic transmission requires localized extracellular catabolism by ecto-nucleotidases into adenosine and channeling to adenosine A1 receptors. J Neurosci 1998, 18:1987-1995.
• [22]Quintas C, Fraga S, Goncalves J, Queiroz G: P2Y receptors on astrocytes and microglia mediate opposite effects in astroglial proliferation. Purinergic Signal 2011, 7:251-263.
• [23]Kettenmann H, Hanisch UK, Noda M, Verkhratsky A: Physiology of microglia. Physiol Rev 2011, 91:461-553.
• [24]Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P: The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 2005, 22:317-330.
• [25]Possel H, Noack H, Putzke J, Wolf G, Sies H: Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 2000, 32:51-59.
• [26]Bruno CJ, Greco TM, Ischiropoulos H: Nitric oxide counteracts the hyperoxia-induced proliferation and proinflammatory responses of mouse astrocytes. Free Radic Biol Med 2011, 51:474-479.
• [27]Ransohoff RM, Brown MA: Innate immunity in the central nervous system. J Clin Invest 2012, 122:1164-1171.
• [28]Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T: Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 2003, 100:8514-8519.
• [29]El-Tayeb A, Qi A, Muller CE: Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem 2006, 49:7076-7087.
• [30]Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA, Weisman GA, Burnstock G: Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003, 24:52-55.
• [31]Mamedova LK, Joshi BV, Gao ZG, von Kugelgen I, Jacobson KA: Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol 2004, 67:1763-1770.
• [32]von Kugelgen I: Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 2006, 110:415-432.
• [33]Braun N, Sevigny J, Robson SC, Enjyoji K, Guckelberger O, Hammer K, Di Virgilio F, Zimmermann H: Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain. Eur J Neurosci 2000, 12:4357-4366.
• [34]Wink MR, Braganhol E, Tamajusuku AS, Lenz G, Zerbini LF, Libermann TA, Sevigny J, Battastini AM, Robson SC: Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) is the dominant ectonucleotidase expressed by rat astrocytes. Neuroscience 2006, 138:421-432.
• [35]Brisevac D, Bajic A, Bjelobaba I, Milosevic M, Stojiljkovic M, Beyer C, Clarner T, Kipp M, Nedeljkovic N: Expression of ecto-nucleoside triphosphate diphosphohydrolase1-3 (NTPDase1-3) by cortical astrocytes after exposure to pro-inflammatory factors in vitro. J Mol Neurosci 2013, 51:871-879.
• [36]Kukulski F, Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF, Robson SC, Kirley TL, Sevigny J: Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 2005, 1:193-204.
• [37]Yu W, Hill WG: Lack of specificity shown by P2Y6 receptor antibodies. Naunyn Schmiedebergs Arch Pharmacol 2013, 386:885-891.
• [38]Bianco F, Fumagalli M, Pravettoni E, D'Ambrosi N, Volonte C, Matteoli M, Abbracchio MP, Verderio C: Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. Brain Res Brain Res Rev 2005, 48:144-156.
• [39]Wen J, Ribeiro R, Zhang Y: Specific PKC isoforms regulate LPS-stimulated iNOS induction in murine microglial cells. J Neuroinflammation 2011, 8:38. BioMed Central Full Text
• [40]Saura J, Angulo E, Ejarque A, Casado V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J: Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 2005, 95:919-929.
• [41]Lipton SA: Neuronal protection and destruction by NO. Cell Death Differ 1999, 6:943-951.
• [42]Villalobo A: Nitric oxide and cell proliferation. FEBS J 2006, 273:2329-2344.
• [43]Gebicke-Haerter PJ, Bauer J, Schobert A, Northoff H: Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. J Neurosci 1989, 9:183-194.
• [44]van Kralingen C, Kho DT, Costa J, Angel CE, Graham ES: Exposure to inflammatory cytokines IL-1beta and TNFalpha induces compromise and death of astrocytes; implications for chronic neuroinflammation. PLoS One 2013, 8:e84269.
• [45]Oberheim NA, Goldman SA, Nedergaard M: Heterogeneity of Astrocytic Form and Function. Methods Mol Biol 2012, 814:23-45.